EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension

Sylwia Dudzicz-Gojowy, Marcin Adamczak

Journal of Clinical Medicine · 17.10.2025 · 14 (20) · 7365

DOI: 10.3390/jcm14207365 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.10.2025. Verfasst von Sylwia Dudzicz-Gojowy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, 40-027 Katowice, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of renin–angiotensin–aldosterone system (RAAS) activity is one of the key mechanisms in the treatment of arterial hypertension. Non-adherence to therapeutic recommendations is considered to be the main cause of failure to achieve therapeutic goals in patients with arterial hypertension. Zilebesiran is the first antihypertensive drug using expression genes modified by siRNA action. The mechanism of action is based on silencing the angiotensinogen gene by activating the RNA-induced silencing complex (RISC). The decreased production of angiotensinogen and storage of siRNA in hepatocyte endosomes makes the drug’s effect prolonged; it may last up to several months after drug administration. In hypertensive patients, a long-term reduction in blood pressure by more than 10 mmHg compared to placebo has been observed after a single dose of zilebesiran. Despite the promising results of the previous studies, further observations are still necessary regarding side effects and long-term effectiveness, as well as the possibility of developing resistance to treatment.

Schlagwörter

Stichwörter der Autor:innen

ACEIs and ARBsarterial hypertensionrenin–angiotensin–aldosterone systemsmall interfering RNAzilebesiran

Autor:innen und Institutionen

  • Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, 40-027 Katowice, Poland.

Zitieren

APA

Dudzicz-Gojowy, S., & Adamczak, M. (2025). Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension. Journal of Clinical Medicine, 14(20), 7365. https://doi.org/10.3390/jcm14207365

Vancouver

Dudzicz-Gojowy S, Adamczak M. Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension. Journal of Clinical Medicine. 2025;14(20):7365. doi:10.3390/jcm14207365

BibTeX
@article{DudziczGojowy2025,
  author = {Dudzicz-Gojowy, Sylwia and Adamczak, Marcin},
  title = {Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {20},
  pages = {7365},
  doi = {10.3390/jcm14207365}
}
Kostenlos starten →